{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T07:49:23Z","timestamp":1782719363969,"version":"3.54.5"},"reference-count":63,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Therapeutic drug monitoring (TDM) is the quantification and interpretation of drug concentrations in blood to personalize pharmacotherapy. Dose adjustment of sertraline is currently based on clinical judgment. Preliminary evidence shows relationships between sertraline blood concentration and clinical outcomes. This review aims to evaluate the clinical utility of TDM of sertraline.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A comprehensive, systematic search of studies in several databases was conducted up to 2025\/06\/26 on the potential relationship between TDM of sertraline and measures of efficacy, safety and tolerability. The search identified 5 clinical trials and 5 observational studies (N = 1106).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The included studies are highly heterogeneous. Most of the results are observational, mainly focused on depression and obsessive-compulsive disorder, covering the whole dosage range, with populations representing the whole life-span, observational periods from 4\u00a0weeks to 1\u00a0year. Efficacy assessments utilized diverse scales and heterogeneous measures of safety\/tolerability. Most of the studies do not detect concentration-effect relationships. Preliminary, non-linear concentration-effect relationships are reported for efficacy and tolerability.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>There is no sufficient evidence for the clinical utility of a generalized use of TDM for sertraline. Preliminary evidence suggests associations between blood concentrations of sertraline and clinical outcomes, potentially supporting the utility of its TDM as guide for clinical judgement in the treatment of depression and obsessive-compulsive disorder, particularly in populations with specific risks. Further studies using symptom-specific clinical scales are needed to assess the potential clinical utility of sertraline TDM in personalized medicine.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic Review Registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/osf.io\/84trm\/overview<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1812662","type":"journal-article","created":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T07:40:41Z","timestamp":1782718841000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical utility of therapeutic drug monitoring of sertraline: a transdiagnostic systematic scoping review"],"prefix":"10.3389","volume":"17","author":[{"given":"Covadonga","family":"Canga-Espina","sequence":"first","affiliation":[{"name":"Department of Psychiatry and Clinical Psychology, Cl\u00ednica Universidad de Navarra","place":["Pamplona, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Pablo","family":"Bullard","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Clinical Psychology, Cl\u00ednica Universidad de Navarra","place":["Pamplona, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bego\u00f1a","family":"Tapia-Alzuguren","sequence":"additional","affiliation":[{"name":"Pharmacy Services, Cl\u00ednica Universidad de Navarra","place":["Pamplona, Navarra, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"G\u0119dek","sequence":"additional","affiliation":[{"name":"Third Department of Psychiatry, Institute of Psychiatry and Neurology","place":["Warsaw, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Aub\u00e1","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Clinical Psychology, Cl\u00ednica Universidad de Navarra","place":["Pamplona, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe","family":"Ortu\u00f1o","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Clinical Psychology, Cl\u00ednica Universidad de Navarra","place":["Pamplona, Spain"]},{"name":"Navarra Institute for Health Research (IdiSNA)","place":["Pamplona, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azucena","family":"Aldaz-Pastor","sequence":"additional","affiliation":[{"name":"Pharmacy Services, Cl\u00ednica Universidad de Navarra","place":["Pamplona, Navarra, Spain"]},{"name":"Navarra Institute for Health Research (IdiSNA)","place":["Pamplona, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricio","family":"Molero","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Clinical Psychology, Cl\u00ednica Universidad de Navarra","place":["Pamplona, Spain"]},{"name":"Navarra Institute for Health Research (IdiSNA)","place":["Pamplona, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,29]]},"reference":[{"key":"B1","first-page":"153","volume-title":"Sigma-1 Receptor Agonists and Their Clinical Implications in Neuropsychiatric Disorders","author":"Albayrak","year":"2017"},{"key":"B2","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1097\/00004583-199804000-00016","article-title":"Sertraline treatment of children and adolescents with obsessive-compulsive disorder or depression: pharmacokinetics, tolerability, and efficacy","volume":"37","author":"Alderman","year":"1998","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"key":"B3","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1089\/cap.2006.16.117","article-title":"Drug concentration monitoring with tolerability and efficacy assessments during open-label, long-term sertraline treatment of children and adolescents","volume":"16","author":"Alderman","year":"2006","journal-title":"J. Child Adolesc. Psychopharmacol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"37","DOI":"10.2165\/00003088-199700321-00006","article-title":"Effect of sertraline on protein binding of warfarin","volume":"32","author":"Apseloff","year":"1997","journal-title":"Clin. Pharmacokinet."},{"key":"B5","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1001\/archpsyc.1961.01710120031004","article-title":"An inventory for measuring depression","volume":"4","author":"Beck","year":"1961","journal-title":"Archives General Psychiatry"},{"key":"B6","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1038\/mp.2009.50","article-title":"Meta-analysis of the dose-response relationship of SSRI in obsessive-compulsive disorder","volume":"15","author":"Bloch","year":"2010","journal-title":"Mol. Psychiatry"},{"key":"B7","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1038\/s41386-019-0554-x","article-title":"Impact of CYP2C19 genotype on sertraline exposure in 1200 Scandinavian patients","volume":"45","author":"Br\u00e5ten","year":"2020","journal-title":"Neuropsychopharmacology"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.17605\/OSF.IO\/84TRM","article-title":"Clinical Utility of Therapeutic Drug Monitoring of Sertraline: A Scoping Review Protocol","author":"Canga-Espina","year":"2025"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1002\/jcph.2457","article-title":"Population pharmacokinetics of sertraline in psychiatric and substance use disorders","volume":"64","author":"Castillo","year":"2024","journal-title":"J. Clin. Pharmacol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1097\/jcp.0b013e31817d79eb","article-title":"Assessment of the prescription of antidepressant drugs in elderly nursing home patients","volume":"28","author":"Cherma","year":"2009","journal-title":"J. Clin. Psychopharmacol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"CD006117","DOI":"10.1002\/14651858.CD006117.pub4","article-title":"Sertraline versus other antidepressive agents for depression","author":"Cipriani","year":"2010","journal-title":"Cochrane Database Syst. Rev."},{"key":"B12","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1055\/s-0043-117891","article-title":"A critical commentary on the 2017 AGNP consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology","volume":"51","author":"de Leon","year":"2018","journal-title":"Pharmacopsychiatry"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.2165\/00003088-200241150-00002","article-title":"Clinical pharmacokinetics of sertraline","volume":"41","author":"De Vane","year":"2002","journal-title":"Clin. Pharmacokinet."},{"key":"B14","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s007020050053","article-title":"Sertraline induced parkinsonim. A case report and an in-vivo study of the effect of sertraline on dopamine metabolism","volume":"105","author":"Di Rocco","year":"1998","journal-title":"J. Neural Transm."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1001\/archpsyc.1989.01810110048007","article-title":"The yale-brown obsessive compulsive scale","volume":"46","author":"Goodman","year":"1989","journal-title":"Archives General Psychiatry"},{"key":"B16","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1001\/archpsyc.1995.03950130053006","article-title":"Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder","volume":"52","author":"Greist","year":"1995","journal-title":"Archives General Psychiatry"},{"key":"B17","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1097\/00004850-199506000-00001","article-title":"A 1 year double-blind placebo-controlled fixed dose study of sertraline in the treatment of obsessive-compulsive disorder","volume":"10","author":"Greist","year":"","journal-title":"Int. Clin. Psychopharmacol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1001\/archpsyc.1995.03950160039008","article-title":"Double-blind parallel comparison of three dosages of sertraline and placebo in outpatients with obsessive-compulsive disorder","volume":"52","author":"Greist","year":"","journal-title":"Archives General Psychiatry"},{"key":"B19","first-page":"218","article-title":"ECDEU assessment manual for","author":"Guy","year":"1976","journal-title":"Psychopharmacology"},{"key":"B20","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1111\/j.2044-8341.1959.tb00467.x","article-title":"The assesment of anxiety states by rating","volume":"32","author":"Hamilton","year":"1959","journal-title":"Br. J. Med. Psychol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","article-title":"A rating scale for depression","volume":"23","author":"Hamilton","year":"1960","journal-title":"J. Neurology Neurosurg. Psychiatry"},{"key":"B22","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1097\/FTD.0000000000001142","article-title":"Update lessons from PET imaging part II: a systematic critical review on therapeutic plasma concentrations of antidepressants","volume":"46","author":"Hart","year":"2024","journal-title":"Ther. Drug Monit."},{"key":"B23","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1097\/FTD.0000000000001264","article-title":"How to determine a therapeutic reference range for a psychotropic drug systematically? Recommendations of the TDM task force of the AGNP","volume":"47","author":"Hart","year":"2025","journal-title":"Ther. Drug Monit."},{"key":"B24","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1002\/CPT.147","article-title":"Clinical pharmacogenetics implementation consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors","volume":"98","author":"Hicks","year":"2015","journal-title":"Clin. Pharmacol. Ther."},{"key":"B25","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1097\/FTD.0000000000000582","article-title":"Concentration\u2013effect relationships of psychoactive drugs and the problem to calculate therapeutic reference ranges","volume":"41","author":"Hiemke","year":"2019","journal-title":"Ther. Drug Monit."},{"key":"B26","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1055\/s-0043-116492","article-title":"Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017","volume":"51","author":"Hiemke","year":"2018","journal-title":"Pharmacopsychiatry"},{"key":"B27","unstructured":"Cochrane handbook for systematic reviews of interventions. version 6.5\n          \n          \n            \n              Higgins\n              J. P. T.\n            \n            \n              Thomas\n              J.\n            \n            \n              Chandler\n              J.\n            \n            \n              Cumpston\n              M.\n            \n            \n              Li\n              T.\n            \n            \n              Page\n              M. J.\n            \n          \n          \n          2024"},{"key":"B28","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/0005-7967(77)90042-0","article-title":"Obsessional-compulsive complaints","volume":"15","author":"Hodgson","year":"1977","journal-title":"Behav. Res. Ther."},{"key":"B29","doi-asserted-by":"publisher","first-page":"109319","DOI":"10.1016\/j.compbiomed.2024.109319","article-title":"Population pharmacokinetic modeling study and discovery of covariates for the antidepressant sertraline, a serotonin selective reuptake inhibitor","volume":"183","author":"Jang","year":"2024","journal-title":"Comput. Biol. Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1515\/CCLM.2000.045","article-title":"Suitability of collection tubes with separator gels for collecting and storing blood samples for therapeutic drug monitoring (TDM)","volume":"38","author":"Karppi","year":"2000","journal-title":"Cclm"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1055\/s-0031-1292290","article-title":"Therapeutic drug monitoring (TDM) in children and adolescents during sertraline therapy","volume":"44","author":"Klampfl","year":"2011","journal-title":"Pharmacopsychiatry"},{"key":"B32","first-page":"5","article-title":"Practice guideline for the treatment of patients with obsessive-compulsive disorder (supplement)","volume":"164","author":"Koran","year":"2007","journal-title":"Am. J. Psychiatry"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1080\/03007995.2022.2096333","article-title":"Paediatric adverse event rating scale: a measure of safety or efficacy? Novel analysis from the MADDY study","volume":"38","author":"Leung","year":"2022","journal-title":"Curr. Med. Res. Opin."},{"key":"B34","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1186\/s12888-025-07033-6","article-title":"Identifying factors related to sertraline concentrations in child\/adolescent and adult patients: insights from a therapeutic drug monitoring service","volume":"25","author":"Li","year":"2025","journal-title":"BMC Psychiatry"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1600-0447.1987.tb10566.x","article-title":"The UKU side effect rating scale: a new comprehensive rating scale for psychotropic drugs and a cross\u2010sectional study of side effects in neuroleptic\u2010treated patients","volume":"76","author":"Lingj\u00e6rde","year":"1987","journal-title":"Acta Psychiatr. Scand."},{"key":"B36","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1034\/j.1600-0447.2000.101005354.x","article-title":"Therapeutic drug monitoring of selective serotonin reuptake inhibitors influences clinical dosing strategies and reduces drug costs in depressed elderly patients","volume":"101","author":"Lundmark","year":"","journal-title":"Acta Psychiatr. Scand."},{"key":"B37","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1097\/00007691-200008000-00014","article-title":"Therapeutic drug monitoring of sertraline: variability factors as displayed in a clinical setting","volume":"22","author":"Lundmark","year":"","journal-title":"Ther. Drug Monit."},{"key":"B38","doi-asserted-by":"publisher","first-page":"115391","DOI":"10.1016\/j.psychres.2023.115391","article-title":"Selection of the optimal dose of sertraline for depression: a dose-response meta-analysis of randomized controlled trials","volume":"327","author":"Luo","year":"2023","journal-title":"Psychiatry Res."},{"key":"B39","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/S0278-5846(01)00314-1","article-title":"Clinical outcome and tolerability of sertraline in major depression: a study with plasma levels","volume":"26","author":"Mauri","year":"2002","journal-title":"Prog. Neuro-Psychopharmacology Biol. Psychiatry"},{"key":"B40","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1002\/hup.502","article-title":"Long-term efficacy and therapeutic drug monitoring of sertraline in major depression","volume":"18","author":"Mauri","year":"2003","journal-title":"Hum. Psychopharmacol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1192\/bjp.134.4.382","article-title":"A new depression scale designed to be sensitive to change","volume":"134","author":"Montgomery","year":"1979","journal-title":"Br. J. Psychiatry"},{"key":"B42","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1186\/s12874-018-0611-x","article-title":"Systematic review or scoping review? Guidance for authors when choosing between a systematic or scoping review approach","volume":"18","author":"Munn","year":"2018","journal-title":"BMC Med. Res. Methodol."},{"key":"B43","first-page":"30","year":"2014","journal-title":"Natl. Inst. Health Care Excell. Bipolar Disorder Assessment Management. Clin. Guideline"},{"key":"B44","doi-asserted-by":"publisher","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","article-title":"The brief psychiatric rating scale","volume":"10","author":"Overall","year":"1962","journal-title":"Psychol. Rep."},{"key":"B45","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1080\/15622975.2022.2134588","article-title":"Characterisation of medication side effects in patients with mostly resistant depression in a real-world setting","volume":"24","author":"Panariello","year":"2023","journal-title":"World J. Biol. Psychiatry"},{"key":"B46","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.11124\/JBIES-20-00167","article-title":"Updated methodological guidance for the conduct of scoping reviews","volume":"18","author":"Peters","year":"2020","journal-title":"JBI Evid. Synth."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1176\/appi.ajp.2011.10111704","article-title":"The columbia\u2013suicide severity rating scale: Initial validity and internal consistency findings from three multisite studies with adolescents and adults","volume":"168","author":"Posner","year":"2011","journal-title":"Am. J. Psychiatry"},{"key":"B48","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1097\/01.pra.0000445247.54048.68","article-title":"Therapeutic drug monitoring (TDM) in psychiatry (part I)","volume":"20","author":"Preskorn","year":"2014","journal-title":"J. Psychiatric Pract."},{"key":"B49","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.jad.2004.02.003","article-title":"Compliance with SSRI medication during 6 months of treatment for major depression:: an evaluation by determination of repeated serum drug concentrations","volume":"82","author":"Reis","year":"","journal-title":"J. Affect. Disord."},{"key":"B50","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1002\/hup.599","article-title":"Serum disposition of sertraline, N-desmethylsertraline and paroxetine: a pharmacokinetic evaluation of repeated drug concentration measurements during 6 months of treatment for major depression","volume":"19","author":"Reis","year":"","journal-title":"Hum. Psychopharmacol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1080\/15622975.2018.1439595","article-title":"TDM in psychiatry and neurology: a comprehensive summary of the consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology, update 2017; a tool for clinicians","volume":"19","author":"Schoretsanitis","year":"2018","journal-title":"World J. Biol. Psychiatry"},{"key":"B52","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1093\/jat\/bkab118","article-title":"Adsorption of therapeutic and recreational drugs during prolonged storage of plasma samples in gel separator tubes","volume":"46","author":"Shepard","year":"2023","journal-title":"J. Anal. Toxicol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.jad.2025.03.017","article-title":"The real-world safety profile of sertraline: pharmacovigilance analysis of the FAERS database","volume":"379","author":"Shu","year":"2025","journal-title":"J. Affect. Disord."},{"key":"B54","doi-asserted-by":"crossref","DOI":"10.1017\/9781108975292","volume-title":"Stahl\u2019s Essential Psychopharmacology","author":"Stahl","year":"2021"},{"key":"B55","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1097\/FTD.0b013e31827a1aad","article-title":"The relation between dosage, serum concentrations, and clinical outcome in children and adolescents treated with sertraline: a naturalistic study","volume":"35","author":"Taurines","year":"2013","journal-title":"Ther. Drug Monit."},{"key":"B56","first-page":"121","volume-title":"The Maudsley\u00ae Prescribing Guidelines in Psychiatry","author":"Taylor","year":"2025"},{"key":"B57","doi-asserted-by":"publisher","first-page":"152301","DOI":"10.1016\/j.comppsych.2022.152301","article-title":"Therapeutic drug monitoring of sertraline in children and adolescents: a naturalistic study with insights into the clinical response and treatment of obsessive-compulsive disorder","volume":"115","author":"Tini","year":"2022","journal-title":"Compr. Psychiatry"},{"key":"B58","doi-asserted-by":"publisher","first-page":"467","DOI":"10.7326\/M18-0850","article-title":"PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation","volume":"169","author":"Tricco","year":"2018","journal-title":"Ann. Intern. Med."},{"key":"B59","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/BF01956868","article-title":"Plasma or serum in therapeutic drug monitoring and clinical toxicology","volume":"10","author":"Uges","year":"1988","journal-title":"Pharm. Weekbl. Sci. Ed."},{"key":"B60","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.medcli.2010.01.015","article-title":"PRISMA declaration: a proposal to improve the publication of systematic reviews and meta-analyses","volume":"135","author":"Urr\u00fatia","year":"2010","journal-title":"Med. Clin."},{"key":"B61","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/1753-2000-2-11","article-title":"Emotional well-being in children and adolescents treated with atomoxetine for attention-deficit\/hyperactivity disorder: findings from a patient, parent and physician perspective using items from the pediatric adverse event rating scale (PAERS)","volume":"2","author":"Wehmeier","year":"2008","journal-title":"Child Adolesc. Psychiatry Ment. Health"},{"key":"B62","doi-asserted-by":"publisher","first-page":"1144573","DOI":"10.3389\/fpsyt.2023.1144573","article-title":"Toward therapeutic drug monitoring of citalopram in depression? Insights from a systematic review","volume":"14","author":"Xu","year":"2023","journal-title":"Front. Psychiatry"},{"key":"B63","doi-asserted-by":"publisher","first-page":"e21230","DOI":"10.1371\/journal.pone.0021230","article-title":"Differences between human plasma and serum metabolite profiles","volume":"6","author":"Yu","year":"2011","journal-title":"PLoS ONE"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1812662\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T07:40:48Z","timestamp":1782718848000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1812662\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,29]]},"references-count":63,"alternative-id":["10.3389\/fphar.2026.1812662"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1812662","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,29]]},"article-number":"1812662"}}